Weiqing Han
Nanchang University · 47 works · 867 citations · h-index 16
Top works
- Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
- Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
- Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial
- Primary gastrointestinal stromal tumor of the prostate: A case report and literature review
- An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).
- Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
- Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
- Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
- The lncRNA Signatures of Genome Instability to Predict Survival in Patients with Renal Cancer
- A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.
- Clinical Effect of Retroperitoneal Laparoscopic Radical Nephrectomy on Renal Cell Carcinoma, the Influence of Renal Function, and the Influencing Factors of Recurrence
- RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.
- Survivin and HLA-I expression predicts survival of patients with clear cell renal cell carcinoma
- Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
- Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
- Comparison of Renal Artery vs Renal Artery-Vein Clamping During Partial Nephrectomy: A System Review and Meta-Analysis
- A single‐centre, open‐label, single‐arm, fixed‐sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients
- Malignant priapism secondary to isolated penile metastasis from a renal pelvic carcinoma
- Abstract CT175: Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study
- Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial